Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus.
Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus.
复制标题
DOI:
10.1016/j.semarthrit.2015.01.002
复制
发表时间:
2015-06
影响因子:
5
通讯作者:
Yazdany J
中科院分区:
文献类型:
--
作者:
Lawson EF;Trupin L;Yelin EH;Yazdany J
To better understand why immunosuppressed individuals with systemic lupus erythematosus (SLE) fail to receive influenza and pneumococcal vaccines. These cross-sectional data derive from the 2009 cycle of the Lupus Outcomes Study (LOS), an annual longitudinal telephone survey of individuals with confirmed SLE. Respondents were included in the analysis if they had taken immunosuppressive medications in the past year. We assessed any prior receipt of pneumococcal vaccine and receipt of influenza vaccine in the past year, then elicited reasons for not receiving vaccination. We used bivariate statistics and multivariate logistic regression to assess frequency and predictors of reported reasons for not obtaining influenza or pneumococcal vaccines. Among 508 respondents who received immunosuppressants, 485 reported whether they had received vaccines. Among the 175 respondents who did not receive an influenza vaccine, the most common reason was lack of doctor recommendation (55%), followed by efficacy or safety concerns (21%), and lack of time (19%). Reasons for not receiving pneumococcal vaccine (N=159) were similar: lack of recommendation (87%), lack of time (7%), and efficacy or safety concerns (4%). Younger, less-educated, non-white patients with shorter disease duration, as well as those immunosuppressed with steroids alone, were at greatest risk for not receiving indicated vaccine recommendations. The most common reason why individuals with SLE did not receive pneumococcal and influenza vaccines was that physicians failed to recommend them. Data suggest that increasing vaccination rates in SLE will require improved process quality at the provider level, as well as addressing patient concerns and barriers.
登录
查看更多内容
影响因子:
5.5
作者:
Taitel, Michael;Cohen, Ed;Pegus, Cheryl
通讯作者:
Pegus, Cheryl
DOI:
10.1002/art.22481
发表时间:
2007-02-15
期刊:
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子:
--
作者:
Yelin, Edward;Trupin, Laura;Panopalis, Peter
通讯作者:
Panopalis, Peter
影响因子:
4.9
作者:
Yazdany, Jinoos;Tonner, Chris;Yelin, Edward H.
通讯作者:
Yelin, Edward H.
影响因子:
5.5
作者:
Mac Donald, R;Baken, L;Nichol, KL
通讯作者:
Nichol, KL
DOI:
10.1002/art.23346
发表时间:
2008-02-15
期刊:
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH
影响因子:
--
作者:
Ward, Michael M.
通讯作者:
Ward, Michael M.